Braveheart Bio (NASDAQ:BRVE) Major Shareholder Acquires $19,800,000.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the transaction, the insider owned 10,232,420 shares of the company’s stock, valued at approximately $184,183,560. This trade represents a 12.05% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Braveheart Bio Stock Down 0.7%

Braveheart Bio stock opened at $25.97 on Friday. Braveheart Bio, Inc. has a twelve month low of $24.61 and a twelve month high of $32.00.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.